Terms: = Breast cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Prognosis
265 results:
1. Crosstalk of disulfidptosis-related subtypes identifying a prognostic signature to improve prognosis and immunotherapy responses of clear cell renal cell carcinoma patients.
Ren L; Liu J; Lin Q; He T; Huang G; Wang W; Zhan X; He Y; Huang B; Mao X
BMC Genomics; 2024 Apr; 25(1):413. PubMed ID: 38671348
[TBL] [Abstract] [Full Text] [Related]
2. Tumor-associated macrophage subtypes on cancer immunity along with prognostic analysis and SPP1-mediated interactions between tumor cells and macrophages.
Xu L; Chen Y; Liu L; Hu X; He C; Zhou Y; Ding X; Luo M; Yan J; Liu Q; Li H; Lai D; Zou Z
PLoS Genet; 2024 Apr; 20(4):e1011235. PubMed ID: 38648200
[TBL] [Abstract] [Full Text] [Related]
3. K48-linked deubiquitination of VGLL4 by USP15 enhances the efficacy of tumor immunotherapy in triple-negative breast cancer.
Wang X; Deng X; Hu J; Zheng W; Ye D; Zhou X; Fang L
Cancer Lett; 2024 Apr; 588():216764. PubMed ID: 38431034
[TBL] [Abstract] [Full Text] [Related]
4. Clinical characteristics associated with efficacy and prognosis among patients treated with pd-1/PD-L1 inhibitors for early-stage triple-negative breast cancers: A meta-analysis.
Wei Y; Wu Y; Luo Y; Ma F
Crit Rev Oncol Hematol; 2024 Apr; 196():104309. PubMed ID: 38423376
[TBL] [Abstract] [Full Text] [Related]
5. Construction of disulfidptosis-based immune response prediction model with artificial intelligence and validation of the pivotal grouping oncogene c-MET in regulating T cell exhaustion.
Li P; Wang S; Wan H; Huang Y; Yin K; Sun K; Jin H; Wang Z
Front Immunol; 2024; 15():1258475. PubMed ID: 38352883
[TBL] [Abstract] [Full Text] [Related]
6. Progress of pd-1/PD-L1 inhibitor combination therapy in immune treatment for HER2-positive tumors.
Zhao S; Qiu Y; Yuan M; Wang Z
Eur J Clin Pharmacol; 2024 May; 80(5):625-638. PubMed ID: 38342825
[TBL] [Abstract] [Full Text] [Related]
7. Circulating blood biomarkers correlated with the prognosis of advanced triple negative breast cancer.
Li X; Zhang Y; Zhu C; Xu W; Hu X; Martínez DAS; Romero JLA; Yan M; Dai Y; Wang H
BMC Womens Health; 2024 Jan; 24(1):38. PubMed ID: 38218823
[TBL] [Abstract] [Full Text] [Related]
8. IFI35 limits antitumor immunity in triple-negative breast cancer via CCL2 secretion.
Xu B; Sun H; Liu S; Liao L; Song X; Wu Y; Hou Y; Jin W
Oncogene; 2024 Mar; 43(10):693-702. PubMed ID: 38216673
[TBL] [Abstract] [Full Text] [Related]
9. CRABP2 regulates infiltration of cancer-associated fibroblasts and immune response in melanoma.
Zeng S; Chen XI; Yi Q; Thakur A; Yang H; Yan Y; Liu S
Oncol Res; 2023; 32(2):261-272. PubMed ID: 38186580
[TBL] [Abstract] [Full Text] [Related]
10. Immune-Checkpoint Inhibitors: A New Line of Attack in Triple-Negative breast cancer.
Jarroudi OA; Bairi KE; Curigliano G; Afqir S
Cancer Treat Res; 2023; 188():29-62. PubMed ID: 38175341
[TBL] [Abstract] [Full Text] [Related]
11. Identification and verification of PTPN3 as a novel biomarker in predicting cancer prognosis, immunity, and immunotherapeutic efficacy.
Zhou Z; Lin Z; Wang M; Wang L; Ji Y; Yang J; Yang Y; Zhu G; Liu T
Eur J Med Res; 2024 Jan; 29(1):12. PubMed ID: 38173048
[TBL] [Abstract] [Full Text] [Related]
12. Guanosine diphosphate-mannose suppresses homologous recombination repair and potentiates antitumor immunity in triple-negative breast cancer.
Ding JH; Xiao Y; Yang F; Song XQ; Xu Y; Ding XH; Ding R; Shao ZM; Di GH; Jiang YZ
Sci Transl Med; 2024 Jan; 16(728):eadg7740. PubMed ID: 38170790
[TBL] [Abstract] [Full Text] [Related]
13. Prognostic and immune infiltration features of disulfidptosis-related subtypes in breast cancer.
Chen S; Li X; Ao W
BMC Womens Health; 2024 Jan; 24(1):6. PubMed ID: 38166898
[TBL] [Abstract] [Full Text] [Related]
14. cancer cell-derived exosomal miR-20a-5p inhibits CD8
Li W; Han G; Li F; Bu P; Hao Y; Huang L; Bai X
Cancer Sci; 2024 Feb; 115(2):347-356. PubMed ID: 38129137
[TBL] [Abstract] [Full Text] [Related]
15. Peripheral B-cell levels predict efficacy and overall survival in advanced melanoma patients under pd-1 immunotherapy.
Liu X; Liu S; Jiang Z; Yang C; Yang X; Li J; Liu H
Immunotherapy; 2024 Mar; 16(4):223-234. PubMed ID: 38126156
[TBL] [Abstract] [Full Text] [Related]
16. ENPP1 is an innate immune checkpoint of the anticancer cGAMP-STING pathway in breast cancer.
Wang S; Böhnert V; Joseph AJ; Sudaryo V; Skariah G; Swinderman JT; Yu FB; Subramanyam V; Wolf DM; Lyu X; Gilbert LA; Van't Veer LJ; Goodarzi H; Li L
Proc Natl Acad Sci U S A; 2023 Dec; 120(52):e2313693120. PubMed ID: 38117852
[TBL] [Abstract] [Full Text] [Related]
17. Impact of disulfidptosis-associated clusters on breast cancer survival rates and guiding personalized treatment.
Chen X; Hu G; Yu Q
Front Endocrinol (Lausanne); 2023; 14():1256132. PubMed ID: 38116315
[TBL] [Abstract] [Full Text] [Related]
18. Analysis of Immune Resistance Mechanisms in TNBC: Dual Effects Inside and Outside the Tumor.
Xu J; Gan C; Yu S; Yao S; Li W; Cheng H
Clin Breast Cancer; 2024 Feb; 24(2):e91-e102. PubMed ID: 38016911
[TBL] [Abstract] [Full Text] [Related]
19. Therapeutic Efficacy of Oxaliplatin and Pembrolizumab Combination Treatment for Triple-Negative breast cancer.
Chu SL
Stud Health Technol Inform; 2023 Nov; 308():341-350. PubMed ID: 38007758
[TBL] [Abstract] [Full Text] [Related]
20. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
[Next]
